Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
157 hedge funds and large institutions have $292M invested in Clovis Oncology, Inc. in 2021 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 57 increasing their positions, 37 reducing their positions, and 26 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 37
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
8% less call options, than puts
Call options by funds: $9.32M | Put options by funds: $10.1M
2% less funds holding
Funds holding: 160 → 157 (-3)
13% less capital invested
Capital invested by funds: $337M → $292M (-$45.3M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$22.9M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.5M |
| 3 |
BlackRock
New York
|
+$3.27M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$3.12M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.56M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$8.29M |
| 2 |
Morgan Stanley
New York
|
-$2.64M |
| 3 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$1.92M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$1.58M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$1.5M |
CLVS Hedge Fund Activity: Q3 2021 in Review
157 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2021, worth a combined $292M — down 13% from $337M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of CLVS and 25 opened new positions — a net loss of 1 holder — while 37 trimmed existing stakes and 57 added.
The largest buyer was State Street, adding an estimated $22.9M. The largest seller was Millennium Management, cutting an estimated $8.29M.
- 157 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2021, down from 160 in Q2 2021.
- Funds reported $292M of Clovis Oncology, Inc. stock for Q3 2021, down 13% quarter-over-quarter.
- 25 funds opened new Clovis Oncology, Inc. positions in Q3 2021 and 26 closed out, a net change of -1 holder.
- The largest Clovis Oncology, Inc. buyer in Q3 2021 was State Street, an estimated $22.9M added.
- The largest Clovis Oncology, Inc. seller in Q3 2021 was Millennium Management, an estimated $8.29M sold.
Based on aggregated 13F filings for Q3 2021.